NASDAQ:PMN Promis Neurosciences (PMN) Stock Price, News & Analysis $8.06 -0.28 (-3.36%) Closing price 03:59 PM EasternExtended Trading$8.32 +0.26 (+3.18%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Promis Neurosciences Stock (NASDAQ:PMN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Promis Neurosciences alerts:Sign Up Key Stats Today's Range$7.74▼$8.8750-Day Range$8.09▼$15.3652-Week Range$6.27▼$27.40Volume21,998 shsAverage Volume91,515 shsMarket Capitalization$72.30 millionP/E RatioN/ADividend YieldN/APrice Target$34.00Consensus RatingModerate Buy Company Overview ProMIS Neurosciences Inc. (NASDAQ: PMN) is a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases. The company’s research focuses on misfolded proteins, which can form toxic structures associated with conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis and other neurological disorders. ProMIS uses its proprietary target-discovery platform to identify disease-specific toxic protein conformations and develop antibodies intended to selectively bind and neutralize them while avoiding healthy forms of the same proteins. Its lead product candidate, PMN310, is an investigational antibody designed to target toxic soluble amyloid-beta oligomers implicated in Alzheimer’s disease. The company has also pursued programs directed at misfolded proteins associated with other neurodegenerative conditions. ProMIS Neurosciences is based in Toronto, Canada, and conducts research and development activities through North American operations and collaborations. The company was founded to advance antibody-based therapies for diseases that have historically been difficult to treat. Its leadership has included Chief Executive Officer Neil McFarlane and co-founder and Chief Scientific Officer Dr. Neil Cashman, a researcher known for work on protein misfolding and neurodegenerative disease.AI Generated. May Contain Errors. Read More Promis Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScorePMN MarketRank™: 3.133798096255 of 5 starsPromis Neurosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 361st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingPromis Neurosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPromis Neurosciences has a consensus price target of $34.00, representing about 321.8% upside from its current price of $8.06.Amount of Analyst CoveragePromis Neurosciences has only been the subject of 3 research reports in the past 90 days.Read more about Promis Neurosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Promis Neurosciences are expected to grow in the coming year, from ($5.07) to ($3.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Promis Neurosciences is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Promis Neurosciences is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Promis Neurosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.78% of the float of Promis Neurosciences has been sold short.Short Interest Ratio / Days to CoverPromis Neurosciences has a short interest ratio ("days to cover") of 7.14.Change versus previous monthShort interest in Promis Neurosciences has recently increased by 3.04%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPromis Neurosciences does not currently pay a dividend.Dividend GrowthPromis Neurosciences does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.95 News SentimentPromis Neurosciences has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Promis Neurosciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PMN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Promis Neurosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Promis Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders1.50% of the stock of Promis Neurosciences is held by insiders.Percentage Held by Institutions50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Promis Neurosciences' insider trading history. Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Promis Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMN Stock News HeadlinesPromis Neurosciences (NASDAQ:PMN) Stock Has Average Target Price of $34.00October 21, 2026 | americanbankingnews.comHC Wainwright Issues Positive Forecast for PMN EarningsOctober 16, 2026 | americanbankingnews.comYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn 100 Into 1000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.October 26 at 1:00 AM | TradeWins (Ad)ProMIS Names Commercial Chief; PMN310 Data Due Q1 2027; Stock DownOctober 6, 2026 | rttnews.comProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial OfficerOctober 6, 2026 | globenewswire.comProMIS Neurosciences to Participate in Upcoming Conferences and Events in SeptemberSeptember 1, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and ProMIS Neurosciences (PMN)August 22, 2026 | theglobeandmail.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsAugust 13, 2026 | finanznachrichten.deSee More Headlines PMN Stock Analysis - Frequently Asked Questions How have PMN shares performed this year? Promis Neurosciences' stock was trading at $6.8250 at the beginning of 2026. Since then, PMN shares have increased by 18.1% and is now trading at $8.06. How were Promis Neurosciences' earnings last quarter? Promis Neurosciences (NASDAQ:PMN) posted its earnings results on Thursday, August, 13th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.38) by $0.10. Read the conference call transcript. When did Promis Neurosciences' stock split? Promis Neurosciences's stock reverse split on the morning of Friday, November 28th 2025.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Promis Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today10/26/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PMN's financial health is in the Yellow zone, according to TradeSmith. PMN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PMN CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees11Year Founded2001Price Target and Rating Average Price Target for Promis Neurosciences$34.00 High Price Target$69.00 Low Price Target$18.00 Potential Upside/Downside+321.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($8.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-143.09% Return on Assets-109.15% Debt Debt-to-Equity RatioN/A Current Ratio7.85 Quick Ratio7.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-13.90Miscellaneous Outstanding Shares8,970,000Free Float8,833,000Market Cap$72.30 million OptionableNot Optionable Beta-0.26 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:PMN) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersIn hindsight, it was all so obviousIntel climbed from $0.50 to $75 between the mid-1980s and 2000. Sun Microsystems surged 19,000% from 1994 to 2...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredReport: OCC clears Trump-linked bankLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
